secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2026-05-13T12:09:13+00:00
Accession:  0001104659-26-059824
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics reports Q1 net loss of $21.6M; cash runway into Q1 2029; CNTY-813 IND on track for 4Q 2026
--------------------------------------------------------------------------------

- Net loss of $21.6M for Q1 2026 vs net income of $76.6M in Q1 2025; R&D $17.1M, G&A $6.6M.
- Cash, cash equivalents and marketable securities $217.0M as of March 31, 2026; runway into Q1 2029.
- CNTY-813 (type 1 diabetes iPSC islet) IND submission on track for 4Q 2026; initial clinical data expected 2H 2027; ADA presentation June 8, 2026.
- CNTY-308 (CD19 CAR-iT) to enter clinic in 2026 pending regulatory clearance; targeting B-cell mediated diseases.
- Completed $135M oversubscribed private placement in January 2026; net cash used in ops $25.3M (down from $34.6M).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465926059824/0001104659-26-059824-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465926059824/tm2614312d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-059824

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer